Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
AbbVie inks $757m migraine-focused deal with Brise PharmaceuticalsÂ
AbbVie and Brise have shared details on this migraine deal two years after the pair originally forged it.
Read Full Article
Pharma Tech
Lonza to acquire five US manufacturing sites from Merck KGaA
Lonza has entered an agreement for the acquisition of five US CDMO sites from Merck KGaA, bringing 1,100 employees into Lonza's workforce.
Read Full Article
Pharma Tech
Bavarian Nordic secures four-year UK vaccine supply deal
Bavarian Nordic has secured a four-year contract from the UK Government to supply its MVA-BN vaccine, used for the prevention of mpox and smallpox.
Read Full Article
Express Pharma
US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavirÂ
Under the existing agreement, injectable lenacapavir will be available at US$40 per person per year across 120 countries covered by Gilead’s voluntary licence. The post US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir appeared first on Express Pharma.
Read Full Article
Pharma Tech
Fresenius and WuXi team up in 37-strong biosimilar development deal
The deal covers assets that target more than €370bn in originator sales.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
Pharma Tech
Nov 3, 2026, 2:21 PM
AbbVie inks $757m migraine-focused deal with Brise PharmaceuticalsÂ
AbbVie and Brise have shared details on this migraine deal two years after the pair originally forged it.
PharmaShots
Nov 3, 2026, 11:36 AM
Merck KGaA to Divest its CDMO Business to Lonza
Shots: Merck KGaA has signed a definitive agreement to divest the CDMO business of its Life Science sector to Lonza for a mid-triple-digit million-euro amount, with closing expected in mid-2027, subject to regulatory approvals & other conditions The deal covers development & manufacturing services for complex modalities across sites in Carlsbad (CA), Madison & Verona… The post Merck KGaA to Divest its CDMO Business to Lonza appeared first on PharmaShots.
PharmaShots
Nov 3, 2026, 11:36 AM
Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US
Shots: Teva & Samsung Bioepis have entered a license & commercialization agreement for 2 FDA-approved immunology biosimilars in the US: infliximab-abda (biosimilar to Remicade) & ETICOVO (etanercept-ykro; biosimilar to Enbrel) Teva will gain US commercialization rights to etanercept-ykro at closing & to infliximab-abda in Q3’27, while Samsung Bioepis remains responsible for regulatory oversight & manufacturing;… The post Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US appeared first on PharmaShots.
PharmaShots
Nov 3, 2026, 11:34 AM
Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon
Shots: Rhythm Pharmaceuticals has amended its global exclusive license agreement with LG Chem for bivamelagon (formerly LB54640), an investigational oral small-molecule MC4R agonist Rhythm will pay 50M in 4 fixed installments through Sep 2029 (0M upfront), while the prior low-to-mid-single-digit royalty is replaced by a 1% royalty on global sales of its MC4R portfolio from… The post Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon appeared first on PharmaShots.
PharmaShots
Nov 3, 2026, 11:34 AM
Cerus Reports Topline Results from the P-III (RedeS) Trial of INTERCEPT Blood System for Red Blood Cells
Shots: Cerus has reported topline results from the P-III (RedeS) trial (NCT03037164) evaluating the INTERCEPT Blood System for red blood cells (RBCs) vs conventional RBCs in patients requiring transfusion support The trial met its 1EP of non-inferiority by adjusted hemoglobin increment in the mITT population (1.996 vs 2.050g/dL; difference: -0.054g/dL; p=0.004), with no significant difference… The post Cerus Reports Topline Results from the P-III (RedeS) Trial of INTERCEPT Blood System for Red Blood Cells appeared first on PharmaShots.
ET Pharma
Nov 3, 2026, 11:08 AM
Alkem names former Zydus executive Dr Amrut Naik new CEO
Dr Naik will succeed Vikas Gupta, who exited Alkem in June this year to head ChrysCapital’s largest pharma buyout Evonith Pharma, formerly known Novartis India, from its Swiss parent.
News
Latest industry coverage
Google News
Nov 3, 2026, 4:41 PM
Principal Secretary (PS) Oluga, French Development Agency (AFD) Discuss Local Pharmaceutical Manufacturing and Digital Health Collaboration - Africa.com
Principal Secretary (PS) Oluga, French Development Agency (AFD) Discuss Local Pharmaceutical Manufacturing and Digital Health Collaboration  Africa.com
Google News
Nov 3, 2026, 4:35 PM
Teva profit beats forecasts, raises 2026 revenue estimates - Reuters
Teva profit beats forecasts, raises 2026 revenue estimates  Reuters
Google News
Nov 3, 2026, 3:55 PM
Pharma Supply Chain Resiliency with Alex Gorsky - J.P. Morgan
Pharma Supply Chain Resiliency with Alex Gorsky  J.P. Morgan
Google News
Nov 3, 2026, 3:37 PM
Teva Pharmaceutical Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - marketscreener.com
Teva Pharmaceutical Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Â Â marketscreener.com
Google News
Nov 3, 2026, 3:31 PM
Shilpa CDMO Invests $50M in Peptide Manufacturing - Contract Pharma
Shilpa CDMO Invests $50M in Peptide Manufacturing  Contract Pharma
Google News
Nov 3, 2026, 3:26 PM
How to Invest in the Rise of China’s Biotech: Buy U.S. Drug Stocks - Barron's
How to Invest in the Rise of China’s Biotech: Buy U.S. Drug Stocks  Barron's
Google News
Nov 3, 2026, 3:23 PM
Axios Live: Virginia looks to schools amid weak funding to sustain biotech growth - Axios
Axios Live: Virginia looks to schools amid weak funding to sustain biotech growth  Axios
Google News
Nov 3, 2026, 3:20 PM
Bayer Q3 2026 slides: pharma momentum drives outlook upgrade - Investing.com
Bayer Q3 2026 slides: pharma momentum drives outlook upgrade  Investing.com
Google News
Nov 3, 2026, 3:13 PM
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo - Reuters
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo  Reuters
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer